The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Prospective phase II study of tumor response assessment by CT and FDG-PET/CT following 8 weekly doses of cetuximab in patients with metastatic/recurrent head and neck squamous cell carcinoma (HNSCC).
J. Ley
No relevant relationships to disclose
B. A. Siegel
No relevant relationships to disclose
F. Dehdashti
No relevant relationships to disclose
J. Subramanian
No relevant relationships to disclose
G. Ansstas
No relevant relationships to disclose
T. Rachocki
No relevant relationships to disclose
J. Mathai
No relevant relationships to disclose
T. M. Wildes
No relevant relationships to disclose
D. I. Kuperman
No relevant relationships to disclose
D. Adkins
Honoraria - ImClone Systems; Lilly